1. Title of Project: Extended-Release Injectable Naltrexone (VIVITROL)

2. Senate Sponsor: Anitere Flores

3. Date of Submission: 01/23/2018

4. Project/Program Description:
   Provide extended-release injectable Naltrexone to DCF-eligible individuals who are addicted to opioids or alcohol.

5. State Agency Contacted? Yes
   a. If yes, which state agency? Department of Children and Families
   b. If no, which is the most appropriate state agency to place an appropriation for the issue being requested?

6. Amount of Non-recurring Requested for fiscal year 2018-19:

<table>
<thead>
<tr>
<th>Amount Requested for Operations</th>
<th>Amount Requested for Fixed Capital Outlay</th>
<th>Total Amount of Requested State Funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,500,000</td>
<td></td>
<td>1,500,000</td>
</tr>
</tbody>
</table>

7. Type, amount and percent of matching funds available for this project for fiscal year 2018-19:

<table>
<thead>
<tr>
<th>Type</th>
<th>Amount</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal</td>
<td>3,800,000</td>
<td>55.9%</td>
</tr>
<tr>
<td>State (excluding the amount of this request)</td>
<td>1,500,000</td>
<td>22.1%</td>
</tr>
<tr>
<td>Local</td>
<td>0</td>
<td>0.0%</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>0.0%</td>
</tr>
<tr>
<td>TOTAL</td>
<td>5,300,000</td>
<td>78.0%</td>
</tr>
</tbody>
</table>

8. Total Project Cost for fiscal year 2018-19 (including the Total Amount of Requested State Funds): 6,800,000

9. Previous Year Funding Details:
   a. Has funding been provided in a previous state budget for this activity? Yes
   b. In the previous 5 fiscal years, how many years was funding provided? (Optional) 3
   c. What is the most recent fiscal year the project was funded? 2017-18
   d. Were the funds provided in the most recent fiscal year subsequently vetoed? No
   e. Complete the following Worksheet.

<table>
<thead>
<tr>
<th>FY:</th>
<th>Input Prior FY Appropriation for this project for FY 2017-18</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Page 1 of 4
10. Is future-year funding likely to be requested?

Yes

a. If yes, indicate non-recurring amount per year.

1,500,000

11. Program Performance:

a. What is the specific purpose or goal that will be achieved by the funds requested?

Provide substance use disorder medication-assisted treatment (MAT) for DCF-eligible individuals who are addicted to opioids or alcohol.

b. What are the activities and services that will be provided to meet the intended purpose of these funds?

Screening and education, medical assessment and lab tests, administration of medication, and medical support/monitoring of patients.

c. How will the funds be expended?

<table>
<thead>
<tr>
<th>Spending Category</th>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative Costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☑ Executive Director/Project Head Salary and Benefits</td>
<td>Salary and benefits for project director.</td>
<td>100,000</td>
</tr>
<tr>
<td>☑ Other Salary and Benefits</td>
<td>Research assistants, training and finance staff.</td>
<td>150,000</td>
</tr>
<tr>
<td>☑ Expense/Equipment/Travel/Supplies/Other</td>
<td>Staff and consultants travel, webinar fees, supplies, and other indirect costs. Site visits.</td>
<td>100,000</td>
</tr>
</tbody>
</table>
d. What are the direct services to be provided to citizens by the appropriations project?

Services include patient screening and medication education, medical assessment, and lab tests, and administration of extended-release injectable naltrexone (VIVITROL). VIVITROL is the only extended release naltrexone product on the market at this time.

e. Who is the target population served by this project? How many individuals are expected to be served?

Target population consists of individuals addicted to alcohol or opioids who are eligible to receive substance abuse treatment and services through the Department of Children and Families. Approximately 150 individuals will be served. Today, there are 41 community providers enrolled in the VIVITROL program. Between November 2015 and November 2017, a total of 2,053 individuals were screened; 1,269 individuals received medical assessments/labs; 1,056 individuals received one or more injections; and 2,930 injections were administered. At January 2018, a total of 266 individuals were actively receiving treatment.

f. What is the expected benefit or outcome of this project? What is the methodology by which this outcome will be measured?

The goal of substance abuse treatment is to facilitate abstinence and long-term recovery in individuals with alcohol or opioid abuse or dependence. The use of research-based MAT protocols is designed to stabilize patients and to promote positive change in the health and well-being of addicted individuals, and to improve retention in other behavioral health programs. DCF currently contracts with the Florida Alcohol and Drug Abuse Association (FADAA) to manage the VIVITROL program. FADAA collects and analyzes data to determine successful MAT participation. Outcome measure: 77% of the patients have been successfully discharged from the VIVITROL program.
g. What are the suggested penalties that the contracting agency may consider in addition to its standard penalties for failing to meet deliverables or performance measures provided for in the contract?
   The current standard penalties for noncompliance are adequate.

12. The owner(s) of the facility to receive, directly or indirectly, any fixed capital outlay funding. Include the relationship between the owner(s) of the facility and the entity.
   N/A

13. Requestor Contact Information:
   a. Name: Mark Fontaine
   b. Organization: Florida Alcohol and Drug Abuse Association
   c. Email: mfontaine@fadaa.org
   d. Phone Number: (850)878-2195

14. Recipient Contact Information:
   a. Organization: Florida Alcohol and Drug Abuse Association
   b. County: Statewide
   c. Organization Type:
      - For Profit
      - Non Profit 501(c) (3)
      - Non Profit 501(c) (4)
      - Local Entity
      - University or College
      - Other (Please specify)
   d. Contact Name: Mark Fontaine
   e. E-mail Address: mfontaine@fadaa.org
   f. Phone Number: (850)878-2195

15. If there is a registered lobbyist, fill out the lobbyist information below.
   a. Name: Frank Mayernick
   b. Firm: The Mayernick Group
   c. Email: Frank@themayernickgroup.com
   d. Phone Number: (850)251-8898